BComments Off on Eleven Biotherapeutics: No Immediate Pipeline And Running Out Of Cash; 70% Downside.
Summary
EBIO’s main drug failed two Phase 3 studies in a row.
However, last month its share price rose 300% on speculation the drug might work after all.
Yesterday EBIO squashed these rumors confirming the… Read more
